| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 1.2K | 14.0% | 14.8% |
| Total Income | 1.2K | 13.7% | 16.5% |
| Expenditure | 1.1K | 9.3% | 14.6% |
| PBT | 99.57 | 51.6% | 9.3% |
| Net Profit | 67.67 | 58.5% | 2.0% |
| OPM | 11.09% | 1.81pp | 8.43pp |
| NPM | 5.67% | 1.60pp | 0.80pp |
| EPS | 4.33 | 62.8% | 1.6% |
Akums Drugs & Pharmaceuticals Ltd. Reports 14.8% Revenue Growth and 21% Adj EBITDA Growth in Q3 FY26
13 Feb 2026 · 13 Feb, 5:42 pm
Summary
Akums Drugs & Pharmaceuticals Ltd., India’s Largest Contract Development and Manufacturing Organizations (CDMO), announced its financial results for the third quarter of FY26. Q3 FY 26 saw strong performance across its key business segments with CDMO revenue growth of over 16% and international branded formulation segment more than doubling sequentially. Adj EBITDA increased 21% YoY to Rs 147 cr and Adj PAT increased 29.5% YoY to Rs 86 cr. The company received EU GMP certification for two of its manufacturing facilities and the first approval from the UK MHRA for Rivaroxaban tablets.
Key Highlights
- 1
14.8% revenue growth in Q3 FY26
- 2
21% Adj EBITDA growth in Q3 FY26
- 3
16% revenue growth in CDMO segment
- 4
More than double sequential growth in international branded formulation segment
- 5
21% YoY increase in Adj EBITDA to Rs 147 cr
- 6
29.5% YoY increase in Adj PAT to Rs 86 cr
- 7
Received EU GMP certification for two manufacturing facilities
- 8
Received first approval from UK MHRA for Rivaroxaban tablets
Management Comments
Mr. Sandeep Jain
Managing Director
The EU GMP certifications reflect the strength of our compliant infrastructure, robust quality systems, and the expertise of our skilled teams. We remain focused on disciplined growth while steadily strengthening our presence in regulated markets.
Mr. Sanjeev Jain
Managing Director
Our continued focus on operational excellence and disciplined growth is aligned with our long-term global vision, enabling us to expand responsibly across regulated markets and strengthen partnerships worldwide.
Informational and educational content only. Not investment advice.